Chidamide
Chidamide is a pharmaceutical drug with 116 clinical trials. Currently 36 active trials ongoing. Historical success rate of 78.6%.
Success Metrics
Based on 11 completed trials
Phase Distribution
Phase Distribution
30
Early Stage
71
Mid Stage
8
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
78.6%
11 of 14 finished
21.4%
3 ended early
36
trials recruiting
116
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/Lymphoma
Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma
The Efficacy of CAPCT in Patients With PTCL
Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
Clinical Trials (116)
Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/Lymphoma
Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma
The Efficacy of CAPCT in Patients With PTCL
Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Chidamide Monotherapy for Intermediate-to-High-Risk Myelodysplastic Syndromes
Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study
Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy
Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.
PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL
Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 116